依那普利
參考文獻

1 2  . Drugs.com. 2020-02-28  [2020-03-13]. （原始内容存档于2021-01-25）.
1 2  . European Medicines Agency. 2023-11-15  [2024-01-20]. （原始内容存档于2024-01-20）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1 2 3 4 5 6  . DailyMed. 2018-11-12  [2020-04-26]. （原始内容存档于2021-08-28）.
1 2 3 4 5 6 7  . The American Society of Health-System Pharmacists.   [2016-12-08]. （原始内容存档于2016-12-21）.
↑  World Health Organization. Stuart MC, Kouimtzi M, Hill SR , 编. . World Health Organization. 2009: 286. ISBN 9789241547659. hdl:10665/44053 .
↑  "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 202310-22.
↑  . Sta tpearls [Internet].   [2024-08-08]. （原始内容存档于2025-02-06）. Enalapril has a boxed warning for fetal toxicity.
↑  Fischer J, Ganellin CR. . John Wiley & Sons. 2006: 467. ISBN 9783527607495. （原始内容存档于2016-12-20） （英语）.
↑  World Health Organization. . Geneva: World Health Organization. 2023. hdl:10665/371090 . WHO/MHP/HPS/EML/2023.02.
↑  . ClinCalc.   [2024-01-14]. （原始内容存档于2024-01-15）.
↑  . ClinCalc.   [2024-01-14]. （原始内容存档于2024-12-27）.
↑  . U.S. Food and Drug Administration (FDA).   [2021-09-24]. （原始内容存档于2024-09-28）.
↑  . MedlinePlus. U.S. National Library of Medicine. October 2010. （原始内容存档于2015-02-08）.
1 2  Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W,  et al. . American Journal of Kidney Diseases. May 2016, 67 (5): 728–741. PMID 26597926. doi:10.1053/j.ajkd.2015.10.011 .
↑  Bangalore S, Fakheri R, Toklu B, Messerli FH. . BMJ (Clinical Research Ed.). February 2016, 352: i438. PMC 4772784 . PMID 26868137. doi:10.1136/bmj.i438.
↑  Mishima E, Haruna Y, Arima H. . Hypertension Research. April 2019, 42 (4): 469–482. PMID 30948820. S2CID 96434746. doi:10.1038/s41440-018-0116-3.
↑  McMurray JJ. . The New England Journal of Medicine. January 2010, 362 (3): 228–238. PMID 20089973. doi:10.1056/NEJMcp0909392. Two large trials showed that when patients with NYHA class II, III, or IV heart failure were treated with enalapril, as compared with placebo, in addition to diuretics and digoxin, the rates of admission to the hospital were reduced, and the relative risk reduction for death was 16 to 40%.
↑  He YM, Feng L, Huo DM, Yang ZH, Liao YH. . Nephrology. September 2013, 18 (9): 605–614. PMID 23869492. S2CID 31791094. doi:10.1111/nep.12134.
↑  Greendyke RM, Bernhardt AJ, Tasbas HE, Lewandowski KS. . Neuropsychopharmacology. April 1998, 18 (4): 272–281. PMID 9509495. doi:10.1016/S0893-133X(97)00159-0 .
↑  Todd PA, Goa KL. . Drugs. March 1992, 43 (3): 346–381. PMID 1374319. S2CID 262278681. doi:10.2165/00003495-199243030-00005.
↑  Menard J and Patchett A. Angiotensin-Converting Enzyme Inhibitors. Pp 14-76 in Drug Discovery and Design. Volume 56 of Advances in Protein Chemistry. Eds Richards FM, Eisenberg DS, and Kim PS. Series Ed. Scolnick EM. Academic Press, 2001. ISBN 9780080493381. Pg 30 的存檔，存档日期2017-09-10.
↑  . emc (electronic medicines compendium). 2023-02-21  [2024-08-24]. （原始内容存档于2025-01-18）.
↑  Given BD, Taylor T, Hollenberg NK, Williams GH. . Journal of Cardiovascular Pharmacology. 1984, 6 (3): 436–441. PMID 6202969. doi:10.1097/00005344-198405000-00010 .
↑  Bryan J. . Pharmaceutical Journal. April 2009, 282 (7548): 455  [2024-08-24]. （原始内容存档于2015-01-26）.
1 2 3  Li JJ. . Li JJ, Corey EJ  (编). . John Wiley & Sons. April 2013. ISBN 9781118354469.
↑  Staff, Drug Discovery Online. 
Patent expiry looms: 18 blockbusters expose $37 billion to generic competition by 2005 的存檔，存档日期2016-05-12. Page accessed 2016-04-23
1 2  . European Medicines Agency. 2023-09-15  [2023-09-21]. （原始内容存档于2023-09-21）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
|  论 编血管紧张素受体调节剂 |
| --- | --- |
血管紧张素受体:  激动剂：血管紧张素Ⅱ  血管紧张素Ⅲ  血管紧张素Ⅳ  L-163,491  肌丙抗增压素 拮抗剂：阿比沙坦  阿齐沙坦  坎地沙坦  依利沙坦  恩布沙坦  依普沙坦  EXP-3174  非马沙坦  福拉沙坦  厄贝沙坦  氯沙坦  米法沙坦  奧美沙坦  奥洛立更  PD123319  泊米沙坦  普拉沙坦  利匹沙坦  沙普立沙坦  斯巴生坦  他索沙坦  替米沙坦  缬沙坦  佐拉沙坦 血管紧张素转换酶抑制剂：阿拉普利  贝那普利  卡托普利  西拉普利  地拉普利  依那普利  依那普利拉  福辛普利  格莫曲拉  咪达普利  赖诺普利  莫西普利  奥马曲拉  培哚普利  喹那普利  喹那普利拉  雷米普利  伦唑普利  利血那明  螺普利  螺普利拉  替莫普利  群多普利  佐芬普利  佐芬普利拉 肾素抑制剂：阿利吉仑  环丙吉仑  地替吉仑  依那吉仑  伊马吉仑  胃酶抑素  雷米克仑  特拉吉仑  占吉仑 前肽：血管紧张素原  血管紧张素Ⅰ 
组合：:  氨氯地平/缬沙坦  奥美沙坦/氨氯地平  奥美沙坦/氨氯地平/氢氯噻嗪  缬沙坦/氢氯噻嗪 
依那普利的三維空間結構。